Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori(Astellas Pharma (Japan)), Sadao Kuromitsu(Astellas Pharma (Japan))
Cited by 254
Related Papers
Synergistic Antitumor Activities of Sepantronium Bromide (YM155), a Survivin Suppressant, in Combination with Microtubule-Targeting Agents in Triple-Negative Breast Cancer Cells
|Biological and Pharmaceutical Bulletin|2013|21
Identification of a novel oncogenic mutation of FGFR4 in gastric cancer
|Scientific Reports|2019|16